Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ramez N Eskander
NRG Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
397 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Moncton Hospital
Moncton, New Brunswick, Canada
- Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
- Health Sciences North
Greater Sudbury, Ontario, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
- Kingston Health Sciences Centre
Kingston, Ontario, Canada
- London Regional Cancer Program
London, Ontario, Canada
- Lakeridge Health Oshawa
Oshawa, Ontario, Canada
- Algoma District Cancer Program Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
- University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- Hopital de la Cite-de-la-Sante
Laval, Quebec, Canada
- Chum - Centre Hospitalier de L'Universite de Montreal
Montreal, Quebec, Canada
- Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
- Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
- Ehime University Hospital
Tōon, Ehime, Japan
- Kure Medical Center and Chugoku Cancer Center
Kure, Hiroshima, Japan
- Niigata University Medical and Dental Hospital
Niigata, Niigata, Japan
- Saitama Medical University International Medical Center
Saitama, Japan
- Centro Comprensivo de Cancer de Upr
San Juan, Puerto Rico
- Keimyung University-Dongsan Medical Center
Dalseo-gu, Daegu, South Korea
- Samsung Changwon Hospital
Seoul, Gyeongsangnam-do, South Korea
- Seoul National University Bundang Hospital
Seongnam, Kyeonggi-do, South Korea
- Kyungpook National University Chilgok Hospital
Daegu, South Korea
- Asan Medical Center
Seoul, South Korea
- Gangnam Severance Hospital
Seoul, South Korea
- Korea Cancer Center Hospital
Seoul, South Korea
- Yonsei University Health System-Severance Hospital
Seoul, South Korea
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Alaska Women'S Cancer Care
Anchorage, Alaska, United States
- Ctca at Western Regional Medical Center
Goodyear, Arizona, United States
- Nea Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
- Kaiser Permanente-Bellflower
Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
- Community Cancer Institute
Clovis, California, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Kaiser Permanente South Bay
Harbor City, California, United States
- Kaiser Permanente-Irvine
Irvine, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Aug 2019
- Primary completion
- 16 Dec 2022
- Completion
- 26 Sept 2026
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 813
- Registry id
- NCT03914612
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.